Court sanction of the Scheme of Arrangement

RNS Number : 7518L

Novacyt S.A.

07 September 2023

 

 

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

 

Court sanction of the Scheme of Arrangement

 

Paris, France and Eastleigh, UK – 7 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today’s announcement by Yourgene Health plc (“Yourgene“), in relation to the recommended cash offer made by Novacyt UK Holdings Limited (“Novacyt UK“), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the “Acquisition“), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme“). A circular in relation to the Scheme was published by Yourgene on 27 July 2023 (the “Scheme Document“).

 

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meaning as set out in the Scheme Document.

 

Further to the announcement made by Yourgene on 17 August 2023 in relation to the passing of the Resolutions required to approve and implement the Scheme at the Court Meeting and the General Meeting, Yourgene has announced that at the Court Sanction Hearing held earlier today the Court issued the Court Order sanctioning the Scheme.

 

There has been no change to the expected timetable of principal events for the Acquisition set out in the Scheme Document. Yourgene’s full announcement regarding the Court Sanction Hearing, including detailed next steps and timetable, can be found here: https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/rmv3p9r

 

 

Contacts

 

Novacyt SA		+44 (0)23 8074 8830
James Wakefield, Non-Executive Chairman James McCarthy, Acting Chief Executive Officer
Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK)			+44 (0)20 7260 1000
Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)			+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit			+33 (1) 42 22 10 10 [email protected] / [email protected]
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Anna Dunphy / Phillip Marriage		+44 (0)20 7933 8780 [email protected]

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world’s most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange’s AIM market (“NCYT”) and on the Paris Stock Exchange Euronext Growth (“ALNOV”).

 

For more information, please refer to the website: www.novacyt.com

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group’s portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene’s Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”.

 

For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.